5 Ergebnisse
CROSS REFERENCE TO RELATED APPLICATION
The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995.
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives.
Nitric Oxide in
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines.
Nitric Oxide in Biology.
The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to pending U.S. application Ser. No. 14/561,091 entitled "Transdermal Cannabinoid Formulations", filed Dec. 4, 2014, now U.S. Pat. No. 9,375,417, issued Jun. 28, 2016, the disclosure of which is hereby incorporated by reference
BACKGROUND
The clinical usefulness of the cannabinoids, including 11.sup.9-tetrahydrocannabinol (/1.sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits, including, but not
BACKGROUND
The clinical usefulness of the cannabinoids, including .DELTA..sup.9-tetrahydrocannabinol (.DELTA..sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits,